AI Theme: Inside the Black Box: How AI Vendors Build, Validate, and Govern Tools for Medical Writing

Generative AI is rapidly entering the clinical regulatory landscape—but most solutions were not designed with the rigor, traceability, and data security expectations required for regulatory writing. For Clinical Study Regulatory Medical Writers, this creates a critical tension: how to leverage AI for speed and efficiency without compromising compliance, data integrity, or inspection readiness.

This 30-minute session introduces ZYLiQ’s approach to secure, closed-loop Gen-AI and why this architectural shift is essential for regulated environments. Unlike prompt-driven, open-context AI tools that rely on fragmented inputs and repeated data handling, closed-loop systems maintain persistent, controlled context—ensuring that source data, narratives, and outputs remain connected, auditable, and secure throughout the writing lifecycle.

Attendees will gain a practical understanding of:

• The limitations and risks of conventional Gen-AI approaches in regulatory settings
• The principles of closed-loop AI and how they align with GxP expectations
• How ZYLiQ enables faster, more consistent generation of clinical safety narratives and regulatory documents without repeated uploads or prompt engineering
• The impact of secure AI workflows on quality, compliance, and writer productivity

This session is designed for regulatory professionals seeking to responsibly adopt Gen-AI while maintaining the highest standards of data governance and regulatory confidence.

This session offers a practice-oriented look at AI-powered tool development and the quality assurance mechanisms required for high-stakes regulatory writing. We will cover three key aspects:

1. Foundational Design for AI Tools: Architecting for Compliance: We examine how developers build and validate AI systems specifically for medical writing tasks to ensure they are “fit for purpose.” This phase explores how medical writers act as advisors during the development stage, setting compliance standards and providing the domain expertise required to guide responsible AI evolution.

2. Co-piloted Workflow Orchestration: Ensuring Narrative Integrity: We look at AI-orchestrated authoring across eCTD documents. This stage highlights human-in-the-loop authoring, end-to-end review, and automated quality control. We show how “change intelligence” maintains narrative integrity and structural consistency during complex data updates.

3. Quality Verification: Benchmarking Regulatory Readiness: We discuss how to measure regulatory readiness through professional benchmark design and task-specific performance assessment. We evaluate five pillars of clinical trust: accuracy, completeness, consistency, factuality, and structural traceability.

 As AI adoption accelerates across pharma, much of the conversation remains focused on capability – what the latest generative models can produce. But in regulated environments, the real challenge is not capability. It’s control.

This session reframes AI risk – not as something to mitigate after deployment, but as something that must be designed for from the outset. By distinguishing between deterministic systems, generative models, and agentic workflows, it highlights how many common risks – including hallucinations, lack of auditability, and governance complexity – stem from applying a single type of AI across fundamentally different tasks.

The discussion will explore practical considerations including data privacy and handling, documentation and traceability, oversight frameworks, and what “responsible use” actually requires in day-to-day operations. It will also address the operational realities of adoption – including user trust, time constraints, and the trade-offs between large-scale transformation and non-intrusive, plug-and-play approaches.

Rather than asking what AI can do, the session focuses on what AI should do – and how to design systems that are not only powerful, but defensible, auditable, and aligned with the realities of regulated work.